|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||2.4985 - 2.6400|
|52 Week Range||1.4700 - 15.4700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.69|
Acreage Holdings, Inc. (“Acreage”) (ACRG-U.CN) (ACRGF) (FSE:0ZV) announced the closing of the transactions contemplated by the previously announced Reorganization Agreement, dated November 15, 2019, among Acreage, Compassionate Care Foundation, Inc. (“CCF”), a New Jersey vertically integrated medical cannabis nonprofit corporation, and certain affiliates thereof, pursuant to which Acreage CCF New Jersey, LLC acquired 100% of the operations of CCF, and, accordingly, Acreage will subsequently consolidate the results of operations of the New Jersey medical cannabis business into its consolidated financial statements. In accordance with the terms of the Reorganization Agreement, Acreage assumed all debts, liabilities and obligations of CCF, including fees, costs and expenses to be incurred by CCF in connection with the dissolution and wind-up of CCF and paid to the former trustees of CCF an aggregate total of $10,000,000 at closing.
U.S. cannabis company Acreage Holdings Inc. took an impairment charge of nearly $200 million in reporting first-quarter earnings Thursday afternoon. The company reported an overall loss of $172 million, or $1.85 a share, on net sales of $24.2 million, up from revenue of $12.9 million a year ago, with most of the losses coming from a pre-tax charge of $196 million that came to $164.7 million after taxes. Acreage said that the charge was related to an earlier restructuring announcement, but noted that the "charge was higher than previously guided due primarily to impairments based on current fair market value in certain states and the write down for its services agreement in Maine, which were not initially contemplated." Acreage stock shot 23.7% higher in Thursday's regular trading session after Canopy Growth Corp. amended its merger agreement to provide capital to the U.S. company. Canopy agreed to acquire Acreage more than a year ago, but can not actually own the company outright until or unless the U.S. legalizes marijuana federally, as Canada has.
Acreage Holdings, Inc. (“Acreage”) (ACRG-U.CN) (ACRGF) (0VZ.F) today reported financial results for the first quarter of 2020. Pro forma revenue* was $37.6 million, a 65% increase compared to the same period in 2019, and a 17% increase compared to the fourth quarter of 2019. Recorded a one-time, non-cash pre-tax charge of $196.0 million, or $164.7 million after taxes, which was associated with Acreage's previously announced strategy to refocus its operations in certain states.
Canadian cannabis company Canopy Growth Corp. said Thursday it has agreed to amend its plan of arrangement with Acreage Holdings Inc. to provide capital to the New York-based Acreage to fund hemp operations. The companies original agreement, announced in April of 2019, allowed Canopy to gain full control of Acreage as soon as cannabis restrictions in the U.S. are lifted. The amended arrangement will provide Acreage shareholders and certain holders of convertible bonds with an upfront payment of $37.5 million, or 30 cents per share. It will also give Acreage shareholders the ability to participate in the upside potential upon the triggering event described above. The amended arrangement will create two classes of Acreage shares, including a new floating share that is not tied to a fixed exchange ratio. "The United States is going to be a core market for Canopy Growth and this new agreement solidifies our path forward with Acreage," said David Klein, Chief Executive Officer of Canopy Growth in a statement. Canopy shares were up 1.1% premarket, but have fallen 21% in the year to date, while the Cannabis ETF has fallen 21% and the S&P 500 has fallen 6%.
Canopy Growth Corporation ("Canopy Growth") (TSX: WEED) (NYSE: CGC) and Acreage Holdings, Inc. ("Acreage") (CSE: ACRG.U) (OTCQX: ACRGF) (FSE: 0VZ), today announced they have entered into an agreement (the "New Agreement") to amend the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, between Canopy Growth and Acreage (the "Arrangement Agreement").
It is secured by, among other items, the Company’s cannabis operations in Illinois, New Jersey and Florida, as well as the Company’s U.S. intellectual property. The Company may pre-pay the note without penalty or premium at any time following the 90th day following the closing. Acreage expects to use the proceeds for working capital and general corporate purposes.
Despite recent troubles, Canopy Growth is optimistic its cannabis beverages can dwarf the growth of hard seltzers.
Shares of Canopy growth (CGC) are trading 30% lower since its latest quarterly results last week. However one analyst sees share as undervalued for the Canadian cannabis company which has shifted from medical to more recreational sales when that market was legalized in Canada almost two years ago. “Although we expect the medical market to shrink because of recreational legalization, we forecast more than 10% average annual growth for the entire Canadian market through 2030, driven by the conversion of black-market consumers into the legal market and new cannabis consumers,” analyst Kristoffer Inton wrote in a note to investors.
U.S. cannabis company Acreage Holdings Inc. said Monday it has entered two funding agreements to raise up to $60 million. The first is a standby equity distribution agreement with an unnamed institutional investor for up to $60 million of its Class A subordinate voting shares, and the second is a private placement in which it issued $11 million in principal amount under a secured convertible debenture for gross proceeds of $10 million. Proceeds of both deals will be used for general corporate purposes and working capital. New York City-based Acreage has an option agreement with Canadian cannabis market leader Canopy Growth Corp. , under which Canopy will take over the company as soon as the federal ban on cannabis has been lifted. Acreage shares were not active premarket, but have fallen 44% in the year to date, while the Cannabis ETF has fallen 16% and the S&P 500 has fallen 6%.
Completion of a private placement offering, in which it issued $11,000,000 in principal amount under a secured convertible debenture, with gross proceeds to the Company of $10,000,000 before transaction fees (the “Convertible Debentures”). For each Subordinate Voting Share purchased under the SEDA (the “Shares”), the Investor will pay the Company the greater of (i) 95% of the lowest daily volume weighted average price of the Subordinate Voting Shares on the Canadian Securities Exchange or other principal market on which the Subordinate Voting Shares are traded (the “Principal Market”) for the five consecutive trading days immediately following the date the Company or the Investor delivers notice requiring the Investor to purchase or the Company to sell the Shares under the SEDA; or (ii) the lowest price allowable under the rules of the Principal Market.
The Company expects this shift in focus will lead to immediate margin improvements and accelerate its pathway to achieve positive pro-forma adjusted EBITDA for the full year 2020. In addition to the sale of some non-core and other under-performing assets, Acreage intends to operate with a more optimized overhead cost structure and corporate team to adapt to an ever-changing cannabis landscape.
This filing gives the Company an additional 15 days to file its Form 10-K and still be deemed to have filed in a timely manner. It is the Company’s current expectation that it will make its Form 10-K filing within the 15-day grace period stipulated by Rule 12b-25. Until the Company has filed the Form 10-K, members of the Company’s management and other insiders are subject to an insider trading black-out period as per its internal Insider Trading and Reporting Policy that is consistent with the principles in Section 9 of National Policy 11-207 - Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.
Acreage expects to file the Annual Filings by no later than May 14, 2020, and the Interim Filings by no later than June 29, 2020. In December 2019, COVID-19 was reported to have surfaced in Wuhan, China, which has and is continuing to spread throughout China and other parts of the world, including the United States. The Company’s operations are located in many states throughout the United States, including New York, one of the areas of the United States hardest-hit by the COVID-19 pandemic.
A webcast will be available and can be accessed via the Acreage’s Investor Relations website http://investors.acreageholdings.com. A playback of the call will be archived on Acreage’s website for approximately 30 days. Headquartered in New York City, Acreage is one of the largest vertically integrated, multi-state operators of cannabis licenses and assets in the U.S., according to publicly available information.
The cannabis sector got a big boost in the last few weeks as governments around Canada and the U.S. confirmed most cannabis stores as essential. While most stores are closing outside of grocery stores, cannabis dispensaries were deemed essential due to their medical cannabis component.Despite early indications of strong demand for cannabis, most of the stocks trade near the recent multi-year lows due to fears the coronavirus outbreak eventually does damage demand. Already, some states are seeing the initial surges in demand wane as businesses were deemed essential, thereby reducing the need to rush into stores during this crisis. Consumers were clearly loading pantries for a long shutdown at home.The obvious negative ramifications for the cannabis sector are tighter credit dynamics potentially forcing weak players out of the sector. The cannabis sector in the U.S. was already struggling with access to reasonable financing options so this extended economic shutdown further benefits the bigger public players with stronger balance sheets and more access to capital.Despite solid indications that cannabis operations are one of the few sectors not impacted by the global economic shutdown, all of the stocks are far off the yearly highs. The opportunity here is to find some stocks not appreciated for their long-term staying power while realizing that provinces and states can always close retail stores similar to the decision in Ontario to close dispensaries for a two-week period.We’ve delved into these three companies with positive outlooks for a strong March quarter and catalysts for higher stock prices in 2020. Using TipRanks’ Stock Comparison tool, we lined up the three alongside each other to get the lowdown on what the near-term holds for these cannabis players.AYR Strategies (AYRSF)A relatively unknown MSO in the U.S. is Ayr Strategies with operations in Massachusetts and Nevada. The stock is down over 70% from the 52-week highs despite impressive quarterly numbers.The stock has a market cap of only $95 million while the company guided to 2020 revenues of $217 million. Ayr Strategies does rely heavily on Nevada dispensaries where a substantial decline in tourist traffic could greatly hit stores with impressive annual revenues of $17 million each prior to the coronavirus outbreak.The U.S. MSO generated Q4 revenues of $32.1 million and an adjusted EBITDA of $9.2 million. The company guided to 2020 EBITDA of nearly $100 million providing substantial ability to weather any protracted economic storm that actually impacts the cannabis sector.Below $6, the stock is a bargain with consensus revenue estimates for 2021 up at $286 million. Right now, the stock trades at nearly half the current 2021 sales estimates showing the market doesn’t appreciate the potential in the U.S. MSO.Overall, AYR Strategies is a Wall Street favorite, earning one of the best analyst consensus ratings in the market. TipRanks analytics exhibit the stock as a Strong Buy. Out of 4 analysts tracked in the last 3 months, 3 are bullish while 1 remains sidelined. With a return potential of 162%, the stock’s consensus target price stands at $13.23. (See AYR Strategies stock analysis on TipRanks)Village Farms (VFF)Another underappreciated cannabis play is Village Farms International. The produce company entered the Canadian cannabis market via a joint venture with Emerald Health Therapeutics called Pure Sunfarms.Despite some ownership hiccups, the venture has been successful in turning produce greenhouses into cannabis operations with the joint venture generating $62.3 million in sales last year. Pure Sunfarms has been very profitable with 76% gross margins and EBITDA of $40.7 million for the year.Recently, the company has seen a dip in revenues due to the tough wholesale market, but wisely Pure Sunfarms has already shifted production to branded sales and has generated the top market share position on the Ontario Cannabis Store. In addition, the company is launching Cannabis 2.0 products along with the now launched branded products in Alberta, British Columbia and Ontario to cover most of the Canadian market outside of Quebec.Village Farms' market valuation stands at ~$160 million, while revenue could reach $150 million in 2020, according to consensus estimates. Furthermore, once the FDA relaxes restrictions on hemp-infused CBD in food products, Village Farms has the ability to quickly ramp up growing operations throughout the U.S, including greenhouses in Texas.The stock only trades at $2.90 after trading above $6.25 back in just January while cannabis sales in Canada only continue to grow.Indeed, every single analyst who's voiced an opinion on the cannabis producer over the past year says this stock is a "buy." On average, analysts who track Village Farms predict the stock will rise more than 18% from its current price to race past $43 per share within the next 12 months. And that makes the stock a "strong buy." (See Village Farms stock analysis on TipRanks)Acreage Holdings (ACRGF)The obvious choice for an underappreciated stock in a tough operating environment is Acreage Holdings. The company had become one of the weaker multi-state operators (MSOs) in the U.S. due to already having a deal with Canopy Growth (CGC) to be acquired at a much higher price.For now, Acreage has 32 operational dispensaries in 13 states with licenses for 88 dispensaries. The company recently opened a dispensary in Florida and has access to other very promising markets.The biggest issue with this MSO is the adjusted EBITDA losses requiring the recent financing transactions. While Acreage appeared somewhat sleepy after the big buyout, the company is now aggressively moving into states like Illinois, Florida, Massachusetts and Michigan to solidify the business in the meantime.Analysts have the company generating sales of up to $405 million in 2021 making the stock more appealing here with ways to win, if the Canopy Growth deal never closes. Acreage is cutting costs and recently furloughed employees to reduce costs during the Covid-19 pandemic with a focus on turning EBITDA profitable this year. The market value is down to only $140 million while the sales are expected to more than double the market cap.Considering the Canopy Growth deal is in stock when the company is legally allowed to trigger the acquisition, the reduced risk helps an investment in Acreage. With Canopy Growth trading at $14, the deal offers shareholders a value of $8.15 with a 0.5818 share conversion. At this point, shareholders should win with or without Canopy Growth.Based on all the above factors, Wall Street analysts are thoroughly impressed with Acreage. With 4 Buy ratings and 1 single hold, the messege is clear: Acreage is a Strong Buy. If this wasn’t enough, the $9.51 average price target implies that shares could surge 491% in the next twelve months. (See Acreage stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Additionally, the merger agreement entered into with Deep Roots Medical, LLC, as described in the Company’s April 18, 2019 press release, was terminated due to the ongoing moratorium imposed by the Nevada Department of Taxation. Acreage also announced the resignation of Steve Hardardt, the Company’s Executive Vice President, Chief People Officer and Administration, effective immediately. With the COVID-19 pandemic resulting in a virtual shutdown of significant parts of the United States that is expected to continue for at least the next month and possibly longer, continued construction and regulatory delays in Illinois, California, Massachusetts, Michigan and elsewhere, and in anticipation of a significant economic downturn that will have a yet-to-be-measured impact on the U.S. cannabis industry, the Company re-evaluated its business plan and determined its most prudent path toward profitability.
“We thank Larissa for her tremendous service to Acreage and wish her every success in the future,” said Acreage Chair and CEO Kevin Murphy. Headquartered in New York City, Acreage is one of the largest vertically integrated, multi-state operators of cannabis licenses and assets in the U.S., according to publicly available information. Acreage is dedicated to building and scaling operations to create a seamless, consumer-focused branded cannabis experience.
Cannabis stocks have not been immune to the market selloff. In fact, Canopy Growth Corp (NYSE:CGC) stock has lost two-thirds of its value in the past six months.Source: Shutterstock But while the outlook has gotten tougher for Canopy in recent months, it is still the best option for cannabis investors today. The rough patch for cannabis stocks may not have reached its low point just yet.But Canopy's management is making all the right moves to ensure the company is well-positioned for the eventual recovery.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn the meantime, Canopy has the strongest balance sheet of its peers. In addition, if the share price continues to decline, Canopy could be an appealing buyout target for minority investor Constellation Brands (NYSE:STZ, NYSE:STZ.B). Canopy Is Making the Right MovesLast year, Canopy fired founder and co-CEO Bruce Linton and replaced him with former Constellation CFO David Klein. Klein is a numbers guy. His first major actions since taking over as CEO demonstrates an aggressive strategy to help shore up the company's financial situation. * 10 of the Best Long-Term Stocks to Buy in a Bear Market Earlier this month, Canopy announced it is shutting down 3 million square feet of production capacity. It also laid off 500 employees and said it would be taking up to a $550 million charge. Following the announcement, Bank of America analyst Christopher Carey said the move was exactly the type of financial discipline he was hoping Klein would bring to the table."While we acknowledge wasteful past spending which preceded today, we think these cuts are the right move for long term, showing mgmt. has the wherewithal to do what is required to create a sustainable, profitable business," Carey says.Canopy has also established itself as an early market leader in Canada with roughly 25% share, according to Bank of America. That share may grow if Canopy's competitors start dropping like flies because of their balance sheets.At the same time, Canopy's conditional buyout of U.S. multi-state operator Acreage Holdings (OTCMKTS:ACRGF) has it well-positioned to take a similar first-mover advantage in the U.S. market should cannabis ever be legalized on a federal level. Canopy Has a Strong Balance SheetThe biggest selling point for CGC stock at this point may be the fact that is has the best balance sheet in the business. Canopy ended 2019 with 1.6 billion CAD in cash and cash equivalents, according to Bank of America. While many of its peers are ramping up debt at any cost to stay afloat, Canopy is actually paying down its debt.Last quarter, Canopy reported just 536 million CAD in long-term debt, down from 842 million CAD in March 2019. Canopy also reported 49% sales growth and just 34% growth in operating expenses. Carey says the capacity and staff cuts will significantly reduce Canopy's working capital drain in coming quarters, improving margins even further.Ultimately, Carey says Canopy will end up in a position of financial strength when the cannabis industry begins to recover."Overall we are favorable to Canopy's long-term prospects, as a leading balance sheet have allowed Canopy to scale both in Canada and abroad (specifically the US), at a faster clip than peers," Carey says. CCG Stock Has Downside ProtectionCanopy also has a major potential catalyst in its back pocket if the share price continues to fall. Constellation Brands took a 38% stake in Canopy for about $4 billion back in August 2018. Since that time, CGC stock is down more than 70%. But Constellation has replaced the Canopy CEO with its own former CFO. Klein is now making bold moves to improve the company's financial situation.I believe there is a distinct possibility Klein was assigned to the position of Canopy CEO to get the company's financial ducks in a row in preparation for a potential Constellation buyout. If Constellation loved taking a 38% stake for $4 billion, it could theoretically get the other 62% of the company today at a price in the $3.5 billion range.The further CGC stock falls during this downturn, the more appealing a buyout will look to Constellation. In that sense, CGC stock has a downside protection that other cannabis stocks do not have.Canopy has a market share lead in Canada and potentially in the U.S. It has a strong balance sheet and improving fundamentals. And it has a financial backer with deep pockets that could potentially buy out the stock at some point. While most of the cannabis group is reeling, CGC stock still looks like a solid long-term investment.Wayne Duggan has been a U.S. News & World Report Investing contributor since 2016 and is a staff writer at Benzinga, where he has written more than 7,000 articles. Mr. Duggan is the author of the book Beating Wall Street With Common Sense, which focuses on investing psychology and practical strategies to outperform the stock market. As of this writing, Wayne Duggan does not hold a position in any of the aforementioned securities. More From InvestorPlace * America's Richest ZIP Code Holds Wealth Gap Secret * 10 of the Best Long-Term Stocks to Buy in a Bear Market * 7 "Perfect 10" Healthcare Stocks to Buy Now * Where the FANG Stocks Sit in This Wild Market The post Canopy Growth Stock Is the Best Coronavirus Cannabis Play appeared first on InvestorPlace.
NEW YORK, March 17, 2020 -- Acreage Holdings, Inc. (“Acreage”) (CSE: ACRG.U) (OTCQX: ACRGF) (FSE: 0VZ), one of the largest vertically integrated, multi-state operators of.
The medical cannabis dispensary is Acreage’s first retail location in the state. With the opening of the dispensary, located at 10520 Spring Hill Road, Acreage now owns or has management services, consulting or other agreements (including pending acquisitions) for 32 operational dispensaries in 13 states, including 14 The Botanist branded dispensaries. Developed by Acreage, The Botanist is both a retail and product brand, deeply rooted in health and wellness, and focused on the holistic power of cannabis to help individuals live balanced lifestyles.
After getting fired as co-CEO at Canopy Growth, Bruce Linton is back with Collective Growth for a cannabis showdown.
As the cannabis sector gained popularity with investors back in 2018, the Canadian stocks garnered far more interest from investors than their U.S. counterparts. The ability of Canadian companies to list on major stock exchanges and their grand global aspirations sent those stock prices soaring. Even after a year of disappointments in Canada, the U.S. stocks still offer far better values for new investors.For 2020, analysts forecast the U.S. cannabis space to dominate the global cannabis markets in term of revenues. More than 50% of the global sales will occur in the U.S. with expectations for the country generating up to $17 billion in sales this year while Canadian sales may only reach $2.5 billion after a December where the monthly total was only $109 million (C$146 million).The real question here is whether international locations including Canada can reach these aggressive targets. The U.S. is set to continue to generate substantial revenue growth even with the federal government not approving cannabis. Federal approval of cannabis offers another bonus to investors in the U.S. market.A lot of the multi-state operators (MSOs) in the U.S haven’t garnered the same investor attention as the large Canadian LPs, but these secondary MSOs are now generating annual sales above $100 million. In addition, most MSOs have built in growth drivers as medical cannabis states approve recreational such as Illinois starting January 1, 2020. Other promising states for the next few years include Arizona, Florida, Ohio and New York.We’ve delved into three stocks providing clear signs the U.S. cannabis space remains even more attractive in 2020. Using TipRanks’ Stock Comparison tool, we lined up the trio alongside each other to get the lowdown on what the near-term holds for these cannabis players.Acreage Holdings (ACRGF)The prime example of the value in the U.S. MSO space in Acreage Holdings. The stock trades below $4 now while having an established right for Canopy Growth to acquire the company at a far higher price.For Q4, Acreage reported $43.6 million in revenues. Revenues were up 90% from last year, but the company still reported a quarterly EBITDA loss of $14.6 million. The revenue number was only up slightly from the Q3 total of $42.2 million.Unlike a lot of the large Canadian LPs that grabbed the stock markets attention last year, the U.S. MSO has the ability to simply expand via opening new stores. The company has the plans to open 10 to 15 new retail dispensaries during the year to bring total dispensaries to 45 and operations in 20 states.The stock will become far more appealing with or without Canopy Growth, if the company can achieve adjusted EBITDA positive goals in the 2H of the year. Acreage plans to cut $7 million in general and administrative costs this year while growing the company via the additional retail store openings and a larger shift into the wholesale market.The good news for investors is the Canopy Growth deal provides investors the right to 0.5818 shares of the Canadian LP when a triggering event occurs allowing the cannabis giant to acquire the company. Canopy Growth currently trades at $17.50 providing for a deal price of $10.18 or approaching 200% upside.What does the Street think? Looking at the consensus breakdown, opinions from analysts are spread out. 2 Buys and 1 Hold add up to a Moderate Buy consensus. In addition, the $11.50 average price target indicates over 220% upside potential. (See Acreage's price targets and analyst ratings on TipRanks)AYR Strategies (AYRSF) AYR Strategies is probably the least known vertically-integrated cannabis MSO. The stock has a market value of only $250 million despite just reporting a quarter with $32.3 million in sales and a positive EBITDA of $9.2 million.The company is a leading MSO with anchor operations in Massachusetts and Nevada. In Nevada, the company has dispensaries averaging an incredible $17 million in annual sales.While the stock has a market cap of only ~$250 million, AYR Strategies forecast 2020 revenues topping $207 million and reaching up to $227 million based on organic growth of 67% to 83%. The company even forecasts an incredible adjusted EBITDA in the range of $100 million.Despite all of these positive numbers, the stock trades down at $9 and far closer to the lows than the highs of nearly $20. The stock trades at only 2.5x EBITDA forecasts while most Canadian stocks trade at far higher multiples of sales while still losing substantial amounts of money.Over the past 3 month, "buy" ratings have outnumbered "holds" two-to-one on AYR Strategies, and the average price target cross all analysts surveyed by TipRanks stands at $15.39. Assuming they're right about that, investors in AYR Strategies today stand to rake in nearly 78% profit over the next year. (See AYR's price targets and analyst ratings on TipRanks)Green Thumb Industries (GTBIF)Last week, Green Thumb Industries opened a sixth retail dispensary in Illinois to sell recreational cannabis. The state had $40 million in sales during the first month of adult-use sales in January and alone will come close to matching current sales levels in Canada that only reached $109 million in December.Green Thumb now has over 40 retail stores, 13 manufacturing facilities and licenses for 96 retail stores in 12 U.S. states. The company reported Q3 revenues of $68 million already placing the company on a revenue path approaching $300 million before even including the potential sales from Illinois. In addition, the company has promising operations in Florida, New York, Ohio and Pennsylvania where future approval of adult-use cannabis will boost sales without the company having to build out new stores or operations.The stock has a market value of $1.5 billion and trades near the yearly lows of the last few years. Green Thump traded as high as $20 all the way back in 2017.Analysts have sales reaching $460 million in 2020 and nearly $700 million in 2021. The stock has far too many catalysts to trade at 2x sales while the Canadian LPs trade at much higher valuations. If these valuations were to remain, the Canadian companies will ultimate look to the U.S. MSOs to acquire businesses once the Federal government approves cannabis in the country.Based on all the above factors, Wall Street also has high hopes for Green Thumb. As 4 Buy ratings were assigned in the last three months compared to single Hold, the consensus rating is a ‘Strong Buy.’ To top it all off, its $17.18 average price target puts the potential twelve-month gain at a whopping 163%. (See Green Thumb's stock-price forecast and analyst ratings)
Acreage Holdings, Inc. (“Acreage” or “Company”) (ACRG-U.CN) (ACRGF) (0VZ.F), one of the largest vertically integrated cannabis operators in the United States, announces today that it has filed a prospectus supplement (the "Supplement") to its short form base shelf prospectus dated August 8, 2019 (the "Base Shelf Prospectus") in connection with its previously-announced US$30 million private placement of special warrants (the “Special Warrants”). Copies of the Base Shelf Prospectus and the Supplement are available under the Company's profile on SEDAR at www.sedar.com. The Company has also filed the Supplement with the United States Securities and Exchange Commission and the Supplement is available under the Company’s profile on EDGAR at www.sec.gov.